{"id":1068505,"date":"2024-04-09T13:01:07","date_gmt":"2024-04-09T17:01:07","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/imugenes-oncolytic-virotherapy-vaxinia-and-b-cell-immunotherapy-her-vaxx-featured-at-the-aacr-annual-meeting-2024\/"},"modified":"2024-08-18T11:48:04","modified_gmt":"2024-08-18T15:48:04","slug":"imugenes-oncolytic-virotherapy-vaxinia-and-b-cell-immunotherapy-her-vaxx-featured-at-the-aacr-annual-meeting-2024","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/imugenes-oncolytic-virotherapy-vaxinia-and-b-cell-immunotherapy-her-vaxx-featured-at-the-aacr-annual-meeting-2024.php","title":{"rendered":"Imugene&#8217;s oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx featured at the AACR Annual Meeting 2024"},"content":{"rendered":"<p><![CDATA[SYDNEY, Australia, April  09, 2024  (GLOBE NEWSWIRE) -- Imugene Limited (ASX: IMU), a clinical stage immuno-oncology company, is pleased to announce poster presentations featuring its CF33 oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx at the American Association for Cancer Research (AACR) Annual Meeting 5-10 April 2024, in San Diego, CA.]]><\/p>\n<p>Visit link:<br \/>\n<a target=\"_blank\" rel=\"nofollow noopener\" href=\"https:\/\/www.globenewswire.com\/news-release\/2024\/04\/09\/2860250\/0\/en\/Imugene-s-oncolytic-virotherapy-VAXINIA-and-B-cell-immunotherapy-HER-Vaxx-featured-at-the-AACR-Annual-Meeting-2024.html?f=22&amp;fvtc=5&amp;fvtv=46634288\" title=\"Imugene's oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx featured at the AACR Annual Meeting 2024\">Imugene's oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx featured at the AACR Annual Meeting 2024<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Visit link: Imugene's oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx featured at the AACR Annual Meeting 2024 <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/imugenes-oncolytic-virotherapy-vaxinia-and-b-cell-immunotherapy-her-vaxx-featured-at-the-aacr-annual-meeting-2024.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246886],"tags":[],"class_list":["post-1068505","post","type-post","status-publish","format-standard","hentry","category-global-news-feed"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1068505"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=1068505"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1068505\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=1068505"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=1068505"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=1068505"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}